RAUDER
8.2.2024 17:03:03 CET | ACCESS Newswire | Press release
This release updates the previous release that posted earlier on Tuesday 6, 2024 to add more information.
PANAMA CITY, PANAMA / ACCESSWIRE / February 8, 2024 / The forum focused on promoting public health policies based on human rights and scientific evidence.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.• Panels addressed the need for legal access to reduced-risk alternatives, such as electronic cigarettes, for millions of smokers.
• Forum's participants signed a manifesto calling on COP10 delegates to avoid prohibition and look at scientific evidence and consumers' perspectives.
Razón Autonomía Derecho A.C, RAUDER, a non-profit civil association that advocates for human rights, personal autonomy, and the free development of personality, organized the "2nd Latin American Nicotine and Risk Reduction Forum: Science, Regulation, and Activism" that took place today in Panama City. The objective was to analyze and discuss the crucial role of reduced-risk alternatives in the fight against tobacco.
The event brought together legislators, experts, doctors, scientists, and activists from across the globe. They emphasized the importance of developing public policies that aim towards harm reduction and respect for human rights, and called for a humane and effective approach, that respects consumers' rights and provides safe, science-based regulated options.
They shared different perspectives around studies and relevant practices from various countries on how alternatives such as vapor products can significantly contribute to harm reduction in smoking. Participants emphasized that their prohibition in countries such as Mexico, Brazil and Panama, has led to an increase in illegal trade and limits smokers' options to access safer alternatives.
"It is essential to recognize and regulate vapor products as reduced-risk alternatives. Prohibition not only prevents smokers from legal options but drives the black market, and gives easier access to minors, besides, all the other negative consequences that it implies," explained Rafael Lara Liy, RAUDER's director.
Doctor Marina Hoyo, a forum's panelist, said: "As health professionals, we have a responsibility to stay up to date, analyze, understand, and question the evidence. But we also need to approach our patient care from a position of empathy towards people seeking to improve their health. That's why we must consider alternatives that reduce risks. This is the foundation of a therapeutic bond that aims to truly help the individual and not stigmatize them, but rather try to alleviate their condition."
Víctor Manuel Salcedo, member of the Chamber of Representatives of Colombia, explained: "Whenever there is a health risk, regulation is necessary. We, as legislators, have the responsibility to act immediately. Our experience indicates that we should regulate, but not prohibit."
The case of other countries, such as Brazil, was also discussed. In Brazil, the ban on vapor products since 2009 has led to an uncontrolled and unsanitary illegal market, affecting millions of smokers, according to Juan José Cirión Lee, President of the organization "México y el Mundo Vapeando." We urge the Brazilian National Health Surveillance Agency (ANVISA) not to miss the opportunity to regulate alternative nicotine consumption products, considering their potential for risk reduction and respect for human rights," he added.
Studies show a significant reduction in smoking rates through reduced-risk alternatives. "The results of studies in Sweden are a clear example of what can be achieved with reduced-risk alternatives. In just 15 years, Sweden has reduced its smoking rates from 15% to 5.6% and has achieved a mortality rate from tobacco-related diseases 39.6% lower than the EU average. This success is attributed to the accessibility, acceptability, and affordability of safer alternatives, combined with balanced regulations and awareness campaigns," explained Roberto Sussman, Researcher at the UNAM Institute of Nuclear Sciences in Mexico.
RAUDER has created an online petition to strengthen the collective voice in defense of human rights, health, and legal access to nicotine alternatives. Those interested in signing the petition or supporting the cause can do so by visiting the dedicated space on the Change.org platform.
The event ended with a manifest that demands all Latin American governments to avoid prohibitions and develop science-based regulatory frameworks. "Our goal is to ensure that smokers have access to less harmful alternatives as part of a comprehensive strategy to reduce the impact of smoking on public health and that our voices are heard. This perspective is especially relevant in the context of the Tenth Conference of the Parties to the WHO Framework Convention on Tobacco Control (COP 10), taking place this week in Panama," added Rafael Lara, Director of RAUDER.
"It is important to emphasize that we share the fundamental goal of protecting public health. We advocate for the voices of consumers to be considered in discussions and decision-making that significantly impact their human rights and global health," Lara emphasized.
About RAUDER
RAUDER, short for Razón, Autonomía y Derecho, A.C., is a non-profit organization composed of experts in various fields of knowledge. Their mission is to promote and defend human rights and their respect in the daily life of society. The organization aims to influence society and public policies with the banner of respect for human rights in all aspects of social development, providing citizens with clarity about which rights they can assert concerning their governing authorities.
PRESS CONTACT:
Abroad: alejandro@nimbus.mx
Contact Information
ALEJANDRO DURAN
PR DIRECTOR
alejandro@nimbus.mx
+525534467248
SOURCE: RAUDER
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Datavault AI Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2025 Accomplishments and Outlook for 20265.2.2026 12:00:00 CET | Press release
Datavault AI signed $49M of Tokenization and Technology Licensing agreements in Q4'25 that impact FY2025 and FY2026 Revenue. Revenue: Datavault AI expects at least $30 million in revenue for FY2025, compared to $2.7 million in FY2024. This represents an increase of more than 1,000% growth in our revenue over 2024. The Company continues to expand to drive substantial near- and long-term accretion to our cash flows and earnings with a revenue target for 2026 of at least $200 million. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / February 5, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, digital engagement and real-world asset (RWA) tokenization technologies, today issued a letter from Nathaniel Bradley, its Chief Executive Officer, to its stockholders highlighting the Company's accomplishments in 2025 and its outlook for 2026. A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER Dear Datavault AI Stockholders, I would like t
AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States4.2.2026 15:45:00 CET | Press release
Industry recognition for the third consecutive year reinforces AGFA HealthCare's clinician-first commitment, and leadership in empowering connected, high-performance imaging environments MORTSEL, BE / ACCESS Newswire / February 4, 2026 / AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide. The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights. AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinica
Preservica Redefines Digital Preservation with Powerful Built-In AI Tools4.2.2026 15:00:00 CET | Press release
OXFORD, UK and BOSTON, MA / ACCESS Newswire / February 4, 2026 / Preservica, the leader in AI-powered Active Digital Preservation™, today announced the rollout of integrated, human-centered AI tools and flexible AI Credits across its product editions. These new features make AI assistance a seamless part of everyday archival workflows, empowering organizations of all sizes to safely adopt AI and scale its use as their needs grow. "With the sheer volume of digital content in backlogs and being created daily, using AI to assist in archival tasks has now become essential" says Stuart Reed, Chief Product Officer at Preservica "Seamlessly integrating human-centered AI tools across our product editions turns AI for Digital Preservation into reality - enabling organizations of all sizes to accelerate routine work, cut backlogs and enhance discovery." Developed in collaboration with Preservica's user community and refined through the company's highly rated AI Workshop series, these embedded to
Karbon-X Files Quarterly Report on Form 10-Q Highlighting Strong Revenue Growth and Commercial Scale4.2.2026 15:00:00 CET | Press release
CALGARY, AB / ACCESS Newswire / February 4, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Quarterly Report on Form 10-Q for the six months ended November 30, 2025. The filing highlights continued momentum in Karbon-X's commercial operations, driven by significant revenue growth and the expansion of its global carbon activities across both compliance and voluntary markets. "Over the past several quarters, we transformed Karbon-X from a developing platform into a scaled, revenue-generating global operator," said Chad Clovis, Chief Executive Officer of Karbon-X Corp. "Revenue increased to $56.5 million (USD), compared to $1.3 million (USD) in the prior-year period, reflecting the strength of our commercial strategy and the growing demand for high-integrity carbon solutions. As we continue to invest in scaling our operations, our expanding global footprint, improved profitability, a
Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant4.2.2026 14:00:00 CET | Press release
Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Alzheimer's disease phase 2 clinical trial (supported by a USD 151 million grant) and, simultaneously, a new platform trial for progressive supranuclear palsy (PSP) (supported by a USD 75 million grant) SAN FRANCISCO, CA / ACCESS Newswire / February 4, 2026 / Axon Neuroscience, a global leader in immunotherapy for human neurodegenerative diseases with an internationally recognized scientific team, announces the achievement of two historic milestones with the potential to significantly influence the future treatment of Alzheimer's disease and progressive supranuclear palsy (PSP): 1. AADvac1 Selected as the First Tau Therapy in the Phase 2 Alzheimer's Tau Platform (ATP) Combination-Therapy Trial An independent panel of leading U.S. scientific and clinical experts selected AADvac1 as the first therapy targeting pathological tau protein to be evaluated in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
